{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Artiva ends autoimmune cell therapy work and plans 94% staff cut","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://imgproxy.divecdn.com/38uMHgItjoFEe23XH9nHGdkYFPdtoE1zPJbdLf_uDh8/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjUwMjcwNjY2LmpwZw==.webp","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/wc7-jowHPmL0vxG-xkbZKq\" style=\"color:#fff;text-decoration:none;\">Artiva ends autoimmune cell therapy work and plans 94% staff cut</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Artiva Biotherapeutics will stop developing its experimental AlloNK cell therapy for autoimmune conditions and lay off 94% of its staff, BioPharma Dive reported. The decision follows two trial partici...</p>\n    </blockquote>"}